Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q04912

UPID:
RON_HUMAN

ALTERNATIVE NAMES:
CDw136; Protein-tyrosine kinase 8; p185-Ron

ALTERNATIVE UPACC:
Q04912; A0A087WZG2; B5A944; B5A945; B5A946; B5A947

BACKGROUND:
The Macrophage-stimulating protein receptor, or p185-Ron, is a receptor tyrosine kinase integral to various physiological processes. It mediates signals essential for cell migration, proliferation, and survival, particularly in response to the MST1 ligand. Its activation promotes epithelial cell migration and macrophage phagocytic activity, playing a significant role in wound healing and immune responses.

THERAPEUTIC SIGNIFICANCE:
The association of the Macrophage-stimulating protein receptor with nasopharyngeal carcinoma underscores its therapeutic significance. Targeting this receptor could lead to breakthroughs in cancer therapy, emphasizing the importance of further research into its functions and mechanisms.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.